CN206102827U - Hierarchical slowly -releasing lacrimal point stopper - Google Patents
Hierarchical slowly -releasing lacrimal point stopper Download PDFInfo
- Publication number
- CN206102827U CN206102827U CN201620585682.1U CN201620585682U CN206102827U CN 206102827 U CN206102827 U CN 206102827U CN 201620585682 U CN201620585682 U CN 201620585682U CN 206102827 U CN206102827 U CN 206102827U
- Authority
- CN
- China
- Prior art keywords
- active agent
- punctal plug
- sustained
- main body
- membrane
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicinal Preparation (AREA)
- Materials For Medical Uses (AREA)
Abstract
The utility model provides a hierarchical slowly -releasing lacrimal point stopper, include: a main bod, the main part has the side of extending between upper end, lower extreme and two terminal surfaces, main part inside has active reagent storage, active reagent storage utensil is in the up end has the opening perhaps being in all there is the opening on up end and the lower terminal surface, the inside active reagent, its characterized in that of containing of active reagent storage the outer surface coating of main part has the degradable membrane, the filter membrane has on the opening. The utility model discloses a hierarchical slowly -releasing, activating agent concentration is controlled well, and the operational time extension reduces and changes the number of times.
Description
Technical field
The utility model belongs to a kind of medical instruments field, more particularly, to a kind of classification sustained release Punctal plug.
Background technology
Treating usually using the method to ocular delivery active agent currently for ophthalmology disease, traditional method is main
It is local application to ocular surface.After ocular local drug delivery, active agent rises to treatment by cornea and in inside ofeye
Concentration, but such mode the disadvantage is that, when reagent adds ocular, it is full of conjunctival sac, cause part overflow eyelid or
Person flows into lacrimal point diluted concentration, and effect is unsatisfactory.
Be born this year many emerging technologies, and what it was most widely used will count the Punctal plug for carrying active agent.Should
Technology adopts Punctal plug and internally adds active agent for container, then Punctal plug is implanted into into lacrimal point, and the method can be effective
The utilization rate of medicine is improved, drug effect is improved.
But active agent Punctal plug is carried at present, also there are some defects, because its active agent for carrying is disposable
Can not supplement, need to be drawn off during next medication, then be implanted into new Punctal plug；Furthermore the dose and concentration of active agent are bad
Control, its active agent is as too little such as dose, needs frequently to change Punctal plug, and dose then causes to waste simultaneously to eye shape very much greatly
Into extra stimulation.
Utility model content
The utility model is to provide a kind of classification sustained release Punctal plug for the problems referred to above, and using classification sustained release, activating agent is dense
The good control of degree, extended durations of action is reduced and changes number of times.
The technical solution of the utility model is：One kind classification sustained release Punctal plug, including：Main body, the main body have upper end,
The side extended between lower end and two end faces, the active reagent storage of the body interior, the active agent storage tool
The upper surface have opening or have on the upper surface and lower surface opening, an active agent storage inside bag
Containing active agent, it is characterised in that the body outer surface is enclosed with degradable membrane, there is filter membrane on the opening.
Further, there is ciliary to protrude outer, cross section of its cross section more than the side for the upper end；The lower end
With eminentia saccularis, cross section of its cross section more than the side.
Further, the degradable membrane at the outer and the eminentia saccularis is thick.
Further, the concentration of active agent is higher than the active agent in the main body in the active agent storage.
Further, the material of main part is the degradation material comprising active agent.
Further, the material of main part is collagen.
Further, the active agent impermeable degradable membrane or can be with micro transmission degradable membrane.
Further, the filter membrane for the degradable membrane that the active agent is unidirectional osmosis, from active agent store by direction
Device is outside.
The terms " active agent " that the utility model is used represents the examination that can treat, suppress or prevent illness or disease
Agent.
Phrase " degradable material " that the utility model is used represented and be typically found in mammal being exposed to
Degrade during bioactivator to the material of detectable degree.
A kind of classification sustained release Punctal plug of the utility model, using degradable membrane parcel carrying active agent by degradable material
The main body of material composition, the active agent storage equipped with high concentration active agent in main body.At the Punctal plug embedded initial stage due to main body
Wrapped up by degradable membrane, only the high concentration active agent in active agent storage discharges active agent by outward opening.When
After degradable membrane outside main body is gradually degraded, the high concentration active agent in active agent storage also exhausts substantially, afterwards main body
The active agent of middle carrying progressively discharges with the degraded of main body.Therefore the utility model is progressively sustained using classification, activating agent
Concentration is controlled well, extended durations of action, is reduced and is changed number of times, and finally without remnants without taking out reduction patient's pain.
Description of the drawings
Fig. 1 is the schematic diagram of first embodiment of the present utility model；
Fig. 2 is the schematic diagram of second embodiment of the present utility model.
In figure：
1st, degradable membrane 2, main body 3, active agent storage
4th, filter membrane
Specific embodiment
The utility model is elaborated below in conjunction with the accompanying drawings.
Embodiment one
As shown in figure 1, a kind of classification sustained release Punctal plug, including：Main body 2, the main body 2 is with upper end, lower end and two
The side extended between end face, the active reagent storage 3 in the inside of the main body 2, the active agent storage 3 is in the upper end
There is opening in face, and the inside of the active agent storage 3 includes active agent, it is characterised in that the outer surface of the main body 2 is enclosed with can
Degradative membrane 1, has filter membrane 4 on the opening.
There is ciliary to protrude outer, cross section of its cross section more than the side for the upper end；The lower end has capsule
Shape swells, cross section of its cross section more than the side.Punctal plug can be fixed on lacrimal point by the outer of the upper end so as to
Will not directly come off and fall in tear stains.The eminentia saccularis of the lower end can be such that Punctal plug is more stably fixed in tear stains.
The degradable membrane 1 at the outer and the eminentia saccularis is thick.The degradable membrane 1 for thickening can extend it
Degradation time, the outer and eminentia saccularis for making the main body is finally degraded, and preventing Punctal plug from shedding into too early in tear stains affects
Effect.
The concentration of active agent is higher than the active agent in the main body 2 in the active agent storage 3.
The material of the main body 2 is the degradation material comprising active agent.Make active agent slow in the degraded of main body
Release.
The material of the main body 2 is collagen.Degradation rate stablizes harmless, and according to specific collagen other medicinal effects can be played
Really.
The active agent impermeable degradable membrane 1 can be with micro transmission degradable membrane 1.Ensure degradable membrane 1
Before degradable, the active agent in main body discharges in advance.
The filter membrane 4 for the active agent for unidirectional osmosis degradable membrane, direction from active agent storage 3 to
Outward.Make the release of active agent more stable steady, thoroughly degrade after its interior high concentration active agent release.
A kind of classification sustained release Punctal plug of the utility model, using the parcel carrying active agent of degradable membrane 1 by degradable
The main body 2 of material composition, there is the active agent storage 3 equipped with high concentration active agent in main body 2.The Punctal plug embedded initial stage by
Wrapped up by degradable membrane 1 in main body 2, only the high concentration active agent in active agent storage 3 by the filter membrane 4 at opening to
Outer release active agent.After the degradable membrane 1 outside main body is gradually degraded, the high concentration active agent in active agent storage 3
Also exhaust substantially, filter membrane 4 also exhausts substantially, the active agent for carrying in main body 1 afterwards progressively discharges with the degraded of main body 1.
The utility model is progressively sustained using classification, and surfactant concentration is controlled well, extended durations of action, and drug effect is steady, together
When can reduce replacing number of times, and final reduce patient's pain without taking out without remnants.
Embodiment two
As shown in Fig. 2 the present embodiment is basically identical with first embodiment, difference is the active agent storage 3
Tool has opening on the upper surface and lower surface.Compared to embodiment one, its feature is in active agent storage 3
The initial stage of active agent release, it is possible to while discharging active agent simultaneously to more than lacrimal point and tear stains inside.
One embodiment of the present utility model has been described in detail above, but the content is only of the present utility model
Preferred embodiment, it is impossible to be considered as limiting practical range of the present utility model.It is all to be made according to the utility model application range
Impartial change with improve etc., all should still belong within patent covering scope of the present utility model.
Claims (8)
1. a kind of classification is sustained Punctal plug, including：Main body, the main body has what is extended between upper end, lower end and two end faces
Side, the active reagent storage of the body interior, the active agent storage tool the upper surface have opening or
There is opening on the upper surface and lower surface, the active agent storage inside includes active agent, it is characterised in that:It is described
Body outer surface is enclosed with degradable membrane, has filter membrane on the opening.
2. a kind of classification according to claim 1 is sustained Punctal plug, it is characterised in that：The upper end has ciliary protrusion outer
Edge, cross section of its cross section more than the side；The lower end has eminentia saccularis, horizontal stroke of its cross section more than the side
Section.
3. a kind of classification according to claim 2 is sustained Punctal plug, it is characterised in that：The outer and the eminentia saccularis
The degradable membrane at place is thick.
4. a kind of classification according to claim 1 is sustained Punctal plug, it is characterised in that：Activity in the active agent storage
The concentration of reagent is higher than the active agent in the main body.
5. a kind of classification according to claim 1 is sustained Punctal plug, it is characterised in that：The material of main part is comprising activity
The degradation material of reagent.
6. a kind of classification according to claim 5 is sustained Punctal plug, it is characterised in that：The material of main part is collagen.
7. a kind of classification according to claim 1 is sustained Punctal plug, it is characterised in that：The active agent impermeable can
Degradative membrane can be with micro transmission degradable membrane.
8. a kind of classification according to claim 1 is sustained Punctal plug, it is characterised in that：The filter membrane is for the activity examination
Agent is the degradable membrane of unidirectional osmosis, and direction is outside from active agent storage.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201620585682.1U CN206102827U (en) | 2016-06-14 | 2016-06-14 | Hierarchical slowly -releasing lacrimal point stopper |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201620585682.1U CN206102827U (en) | 2016-06-14 | 2016-06-14 | Hierarchical slowly -releasing lacrimal point stopper |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN206102827U true CN206102827U (en) | 2017-04-19 |
Family
ID=58509596
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201620585682.1U Expired - Fee Related CN206102827U (en) | 2016-06-14 | 2016-06-14 | Hierarchical slowly -releasing lacrimal point stopper |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN206102827U (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111228034A (en) * | 2020-01-16 | 2020-06-05 | 贵州省人民医院 | Drug-loading controlled-release lacrimal duct embolus and preparation method thereof |
-
2016
- 2016-06-14 CN CN201620585682.1U patent/CN206102827U/en not_active Expired - Fee Related
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111228034A (en) * | 2020-01-16 | 2020-06-05 | 贵州省人民医院 | Drug-loading controlled-release lacrimal duct embolus and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12076272B2 (en) | Conjunctival cover and methods therefor | |
| US3826258A (en) | Gradual release medicine carrier | |
| CN203915219U (en) | Lacrimal ductule resistance core | |
| CN101357242A (en) | Structure for modulating intraocular pressure | |
| TW201039805A (en) | Punctal plugs | |
| WO2016031535A1 (en) | Device placed under eyelid | |
| JPH1033584A (en) | Lacrimal duct insertion appliance | |
| CN206102827U (en) | Hierarchical slowly -releasing lacrimal point stopper | |
| Filippello et al. | Reply: Efficacy and safety of transepithelial corneal collagen crosslinking | |
| CN109172129A (en) | Glaucoma Valve drainage device | |
| WO2015066616A1 (en) | Conjunctival cover and methods therefor | |
| CN205108047U (en) | Glaucoma drainage device | |
| CN212326728U (en) | Epithelial trephine for corneal cross-linking operation | |
| Livingston et al. | A study of the effects of liquid mustard gas upon the eyes of rabbits and of certain methods of treatment | |
| CN214967611U (en) | Automatic control device for intracameral puncture drainage intraocular pressure | |
| RU94150U1 (en) | OPHTHALMOLOGICAL DEVICE FOR RETAINING THE MEDICINE ON THE CORNERAL SURFACE | |
| Xu et al. | EFFICACY, SAFETY, AND BIODEGRADATION OF A DEGRADABLE SCLERAL BUCKLE OF CHITOSAN–GELATIN POLYMER IN RABBITS | |
| CN220391989U (en) | Sterilized dressing packaging bottle for hyaluronic acid | |
| CN209790092U (en) | temporary artificial eye piece | |
| CN214857535U (en) | Disposable sterile vitreous cavity injection bag | |
| CN218552773U (en) | Artificial artificial eye slice with medicine-carrying hydrogel layer | |
| CN210932193U (en) | Medical device for correcting conjunctival laxity and maintaining normal form of conjunctival sac | |
| CN211674861U (en) | Ophthalmic injection and suction device | |
| Chung et al. | Diplopia and periorbital mass associated with Miragel buckling explant | |
| CN208552234U (en) | Eye dressing |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20170419 Termination date: 20180614 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |